UK Markets open in 44 mins

MorphoSys AG (MOR.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
19.63+0.54 (+2.83%)
At close: 05:35PM CEST
Full screen
Previous close19.09
Open19.09
Bid19.52 x 1500
Ask19.55 x 8800
Day's range18.90 - 19.99
52-week range16.45 - 72.84
Volume165,103
Avg. volume240,415
Market cap670.188M
Beta (5Y monthly)0.85
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    MorphoSys AG Reports Outcome of Annual General Meeting 2022

    DGAP-News: MorphoSys AG / Key word(s): AGM/EGMMorphoSys AG Reports Outcome of Annual General Meeting 2022 18.05.2022 / 22:02 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 18, 2022MorphoSys AG Reports Outcome of Annual General Meeting 2022All Proposed Resolutions ApprovedMorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at

  • EQS Group

    MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings

    DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings 12.05.2022 / 16:45 The issuer is solely responsible for the content of this announcement.Media ReleaseBOSTON, Mass., USA, May 12, 2022MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EH

  • EQS Group

    MorphoSys AG Reports First Quarter 2022 Financial Results

    DGAP-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2022 Financial Results 04.05.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 4, 2022MorphoSys AG Reports First Quarter 2022 Financial Results- Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth- NCCN® updated the designation of Monjuvi to preferr